We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Court Rules Mylan’s Generic Uroxatral Would Infringe Sanofi’s Patent
Court Rules Mylan’s Generic Uroxatral Would Infringe Sanofi’s Patent
May 18, 2010
A federal court has ruled that Mylan Pharmaceuticals’ proposed generic version of the prostate treatment Uroxatral would infringe and induce others to infringe Sanofi-Aventis’ patent on the drug.